Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Real-world utilization of tissue-free ctDNA monitoring in patients with prostate cancer.
Kase, Adam M. , Johnson, Marcela A. , Lam, E., Zhu, Xinhua, King, Jonathan Douglass, Zurita, Amado J. , Tambaoan, Candice Francheska, Quintanilha, Julia, Tukachinsky, Hanna, Gascó, Amaya, Hoimes, Christopher , Tambaoan, Candice Francheska B. , Quintanilha, Júlia C.F. , Tukachinsky, Hanna , Childress, Merrida

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 98-98

10.1200/jco.2026.44.7_suppl.98 Get It

98 Background: Circulating tumor DNA (ctDNA) monitoring provides an additional clinical tool for assessing treatment response and emerging resistance. We evaluated the real-world (RW) use and results of FoundationOne Monitor (F1Monitor), a tissue-free ctDNA monitoring assay, in patients (pts) with prostate cancer (PCa). Methods: The clinical laboratory developed test, F1Monitor, was available to physicians in a limited pilot with full discretion of test eligibility, timing, and frequency. Therapy type was a non-mandatory field on the order form. CtDNA was detected and quantified by ctDNA tumor fraction (TF); variants were tracked with variant allele frequency (VAF), and the origin [tumor somatic (TS), germline, or clonal hematopoiesis (CH)] was predicted algorithmically. Results: F1Monitor was ordered by 28 physicians for 215 pts with PCa. Therapy data were known for 156 pts: ADT+ androgen receptor pathway inhibitor (ARPI, N = 69/156 pts, 44%), ADT alone (N = 32, 21%), ADT + chemotherapy (chemo, N = 20,13%), ADT + radioligand therapy (RLT, N = 17, 11%), and others (N = 18). Median follow-up was 188 days. Longitudinal testing (≥2 tests) occurred in 64 pts, often (N = 37) when the first test was ctDNA TF positive (+). Median cadence for serial testing (≥3 tests, N = 31) was 42 days (IQR: 35, 59). ctDNA TF was + at any timepoint in 50% (107/215) of pts overall and 53% (82/156) of pts known to be on therapy, trending higher in pts on ADT+chemo (80%) and ADT+RLT (65%). Median and maximum ctDNA TF values were 11% (IQR: 0.9,37.8%) and 89% respectively. Lowest ctDNA TF and reportable TS VAF quantified were 0.13% and 0.04%, respectively. ctDNA TF longitudinal changes were observed in 67% (43/64) of pts: 92% of pts on ADT+chemo, 69% on ADT+RLT, 59% on ADT+ARPI, and 38% of pts on ADT alone. Among pts with ≥2 tests, 39% (25/64) had ctDNA TF increase, including 6/27 (22%) pts that were ctDNA TF negative (-) on the first test. Of pts with ≥2 tests and any ctDNA TF+ result, 35% cleared ctDNA TF in later tests. 33% of pts were persistently ctDNA TF -. Each test reported an average of 5 alterations: ~2 TS short variants, copy number variants, or rearrangements, and ~2 predicted CH variants. HRR variants were detected in 37% (80/215) of pts (31 with ≥2 tests) : persistent in 20 pts, cleared in 7, and newly emerging in 14. At least 50% of alterations in CHEK2 and ATM were predicted CH. Alterations in PI3K pathway genes were detected in 20% (43/215) of pts: (16 with ≥2 tests) persistent in 6 pts, cleared in 5, and newly emerging in 5. Conclusions: In this RW pilot of tissue-free ctDNA monitoring in PCa, F1Monitor demonstrated high sensitivity in clinical practice, detecting ctDNA TF as low as 0.13% and TS VAF as low as 0.04% while distinguishing tumor-derived from predicted CH variants. Importantly, ctDNA TF was + in 53% of pts while on therapy with observed longitudinal changes for 67% of pts, supporting potential utility of ctDNA for monitoring treatment response and emerging resistance.
Microbiome and Vocalization Biomarkers of Infant Distress, Maternal Depression and Parenting Styles
Ligezka, Anna, Lynch, Brian , Saliba, Maria , Corral-Frias, Martha, Johnson, S., Chen, Jun, Allen, Summer V. , Frank, Jennifer M., Voort, Jennifer L. Vande, Croarkin, Paul E. , Romanowicz, Magdalena , Lynch, Brian A , Vande Voort, Jennifer L , Croarkin, Paul E , Ligezka, Anna N. , Chen, Jun, Voort, Jennifer L. Vande

Mayo Clinic

Chronic Stress | March 2, 2026 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/24705470261425120 | PMID 41782637 Get It

Introduction Psychiatric disorders have their genesis in early life. Standard screening approaches during well child visits for pathological infant distress, maternal depression, and dysfunctional parenting behaviors are likely inadequate. Microbiome measures and infant vocalizations have promise as scalable psychiatric biomarkers for infants. The purpose of this study was to examine associations among infant gut colonization based on microbiome measurements with maternal distress and maternal depressive symptoms in a sample of infants. Methods This study sought to examine infant microbiome correlates of infant distress, parent-infant interactions, maternal distress, and maternal depressive symptoms. We collected ( N = 31) microbiome samples, infant vocalizations during vaccination, and behavioral measures during a 4 month well child visit (WCV) and did a battery of clinical assessments to assess for maternal depression, parent-child interactions, family characteristics and family stress. Whole-genome SHOTGUN sequencing was utilized to identify three types of associations: alpha-diversity using Shannon and Inverse-Simpson indexes, beta-diversity using Bray-Curtis and Jaccard distances, and differential abundance using LinDA. Spectral measures of infant cries were also modeled to assess potential relationships with clinical assessments and the microbiome. Results There were 19 phyla, 417 genera, and 1246 species identified with taxonomic classification. Maternal distress as measured by PHQ-9 scores obtained when infants were 2 months old were associated with 4 bacterial species ( Actinomyces johnsonii, Bilophila wadsworthia, Clostridium dakarense and Ruminococcus flavefaciens ; FDR < 0.1) and beta-diversity ( p = 0.006-BC; p = 0.005-Jaccard). Infant cries with greater high frequency band power ( p < 0.03) and a greater high-to-mid frequency ratio–metrics ( p < 0.05) were associated with altered α-diversity of the microbiome. No correlations were present between maternal PHQ-9 at 4 months, PSI-IV and microbiome diversity. Conclusion The present findings suggest that an infant stress (assessed by quality of crying) is associated with lower microbiome diversity. Decreased diversity reflects an unhealthy microbiome. Parental depressive symptoms may also influence infant microbiome. Future interventional studies focused on the quality of the infant-caregiver relationship should examine related changes in intestinal microbiota.
A Hemodynamic Lens on Inspiratory Muscle Strength Exercise
Yeo, Dongwook , Johnson, Bruce D., Kim, Chul-Ho, Kim, Chul‐Ho , Kim, Chul-Ho , Johnson, Bruce D.

Mayo Clinic

The Korean Journal of Sports Medicine | February 27, 2026 | Volume: 44 | Issue: 1 | Pages: 1-3

10.5763/kjsm.2026.44.1.1 Get It

Total Thyroidectomy vs Lobectomy for Sporadic Medullary Thyroid Cancer
Lincango, Eddy, Vilatuna-Andrango, Luis, Arce-Camposano, Andrea, Mena-García, Cristina, Figueroa, Luis, Herold, Sarah, Zaldumbide, Matias, Pacheco, Fernanda Ventorim , Cayambe, Jennifer, Romero-Velez, Gustavo, Diaz, Jose Matias Zaldumbide , Lincango, Eddy P., Zaldumbide Diaz, Jose Matias , Lincango-Naranjo, Eddy , Andrango, Luis Vilatuna, Zaldumbide, Jose Matias, Pacheco, Fernanda, Quilligana, Jennifer Marisol Cayambe , Solís-Pazmiño, Paola , Westmoreland, Tamarah J. , Lew, John I. , Drake, Frederick Thurston , Romero-Vélez, Gustavo , Sosa, Julie Ann , Brito, Juan P.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | February 26, 2026 | Volume: 152 | Issue: 4 | Pages: 400

10.1001/jamaoto.2025.5599 | PMID 41746657 Get It

Importance Total thyroidectomy is the established surgical standard for hereditary and sporadic medullary thyroid cancer (sMTC). However, for unilateral sporadic tumors, its benefit over lobectomy remains uncertain. Objective To compare oncologic outcomes between total thyroidectomy and lobectomy in patients with sMTC. Data Sources and Study Selection MEDLINE, Embase, Scopus, and Cochrane Central Register of Controlled Trials were searched from inception to December 2025 to identify comparative studies on patients with sMTC who underwent total thyroidectomy or lobectomy. Data Extraction and Synthesis Reviewers working independently and in duplicate screened titles, abstracts, and full-text articles for eligibility using standardized instructions. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses ( PRISMA ) and Meta-Analysis of Observational Studies in Epidemiology ( MOOSE ) guidelines were used for reporting. Main Outcomes and Measures Primary outcomes were mortality, overall survival, structural recurrence, biochemical cure, and distant metastasis development. The secondary outcome was postoperative complications. Effect measures were calculated as odds ratios (ORs) or relative risks (RRs) with 95% CIs using a random-effects model. The risk of bias was assessed using the Newcastle-Ottawa Scale. Results Nine retrospective studies met inclusion criteria and comprised 1371 patients (295 of 397 patients [74.3%] with documented sex were female, and median age ranged from 45.0 to 58.2 years). A total of 531 patients (38.7%) underwent lobectomy and 840 (61.3%) underwent total thyroidectomy. Of 341 tumors, 280 (82.1%) lacked extrathyroidal extension, 284 of 401 tumors (70.8%) measured smaller than 2 cm (70.8%), and 197 of 343 tumors (57.4%) were node negative; central neck dissection was performed in 445 of 492 patients (90.4%). Multifocal disease was uncommon and reported in 30 of 330 patients (9.1%). Mortality did not differ at 5 years (RR, 0.30; 95% CI, 0.07-1.35) or beyond (RR, 1.00; 95% CI, 0.40-2.47). Overall survival at 5 years was similar (RR, 1.02; 95% CI, 0.94-1.11). Total thyroidectomy was not associated with lower structural recurrence rates at 5 years (OR, 0.45; 95% CI, 0.14-1.49), but it was associated beyond 5 years (OR, 7.26; 95% CI, 1.07-49.21). No differences were observed for biochemical cure at 5 years (OR, 0.86; 95% CI, 0.47-1.56) or beyond 5 years (OR, 0.87; 95% CI, 0.26-2.89). Distant metastasis development did not differ at 5 years (OR, 1.64; 95% CI, 0.09-31.52). Sensitivity analyses revealed no differences across any outcomes. Postoperative complications were more common in total thyroidectomy. Risk of bias was high in 4 studies, moderate in 4, and low in 1. Conclusions and Relevance Findings in this systematic review and meta-analysis, based on data from retrospective studies, suggest that thyroid lobectomy may be associated with oncologic outcomes comparable to total thyroidectomy in selected patients with sMTC.
Sarcomatoid urothelial carcinoma with constitutive PD-L1 overexpression
Gupta, Sounak, Kosari, Farhad , Thapa, Prabin , Murphy, Stephen J, Johnson, Sarah H. , Dashti, Nooshin K. , Tekin, Burak, Dasari, Surendra, Kipp, Benjamin R. , Sharma, Vidit, Shah, Paras H, Orme, Jacob J. , Frank, Igor, Karnes, R Jeffrey, Boorjian, Stephen A, Vasmatzis, George , Cheville, John C, Zarka, Jabra G, Orme, Jacob J , Murphy, Stephen J. , Greipp, Patricia T. , Tekin, Burak , Zarka, Jabra , Sharma, Vidit , Shah, Paras H., Frank, Igor, Karnes, R. Jeffrey, Boorjian, Stephen A. , Cheville, John C.

Mayo Clinic

Am J Clin Pathol | February 26, 2026 | Volume: 165 | Issue: 4 | Pages: No page available

10.1093/ajcp/aqag023 | PMID 41969028 Get It

Abstract Objectives Sarcomatoid urothelial carcinoma (sUC) is associated with poor clinical outcomes. Herein, we evaluated clinicopathologic features (including PD-L1 expression) for institutional cases. Methods Sixty-five patients with sUC treated by radical cystectomy were matched for age, sex, and pathologic stage to 190 patients with pure urothelial carcinoma (UC). Outcomes were evaluated using the Kaplan-Meier method. Immunohistochemistry (IHC) results for tumor-specific PD-L1 expression in sUC were quantified using H-scores (range, 0-300). Cases with constitutive PD-L1 expression (cPD-L1; H-score ≥240) were evaluated for amplification events using fluorescence in situ hybridization (n = 28), mate-pair sequencing (Mpseq; n = 6), RNA sequencing (n = 5), and targeted next-generation sequencing (n = 8). PD-L1 regulatory pathways were evaluated using gene set enrichment analysis in the Cancer Hallmark dataset. Results Most patients with sUC had advanced disease (≥pT2, 62/65, 95%), without significant differences in overall and cancer-specific survival, when matched to pure UC. Median PD-L1 H-scores using different clones were 100 (SP142), 120 (SP263), and 195 (22C3). cPD-L1 was seen in 43% (28/65) of cases of sUC that were enriched for TP53, TERT, and CDKN2A/B alterations. PD-L1 amplification was identified in 7 (of 28, 25%) of these cases. Bionformatics analysis consistently identified IL6-JAK-STAT3 and interferon α/γ signaling in sUC with cPD-L1 expression. Conclusions Our results suggest that cPD-L1 expression in most sUC occurs secondary to IL6-JAK-STAT3 and interferon α/γ signaling. This provides a biologic rationale for evaluating response to immunotherapy in this patient population.
Demographic factors and rural residence history associated with smoking history
Reed, Tyra, Gordon, Destiny, Dyal, Brenda W. , KL, Powell-Roach, Ezenwa, Miriam O. , Johnson-Mallard, Versie, Odedina, Folakemi T., Yao, Yingwei, Wilkie, Diana J. , Powell-Roach, Keesha , Powell-Roach, Keesha , Krieger, Janice L. , Wilkie, Diana J , Johnson‐Mallard, Versie

Mayo Clinic

Journal of the American Association of Nurse Practitioners | February 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/jxx.0000000000001257 | PMID 41733483 Get It

Background: Understanding personal and geographic factors associated with smoking is important to design and implement interventions focused on reducing cancer health disparities. Scant research has been published recently regarding factors associated with smoking history associations within rural communities. Purpose: To examine demographic factors and rural residence history for associations with smoking history. Methodology: In a cross-sectional study of cancer-related behaviors, 1,786 adults (mean age 47.9 ± 17.5 years; 53% female, 84% White) completed an online survey in 2020. We examined factors associated with smoking history (having smoked at least 100 cigarettes) using independent t-tests, chi-square tests, and logistic regression. Results: Of the participants, 36% had a rural residence history and 49% had a smoking history. A larger proportion of men than women (61% vs. 37%; p < .001), White than Black participants (50% vs. 39%; p = .001), and rural than nonrural residents (53% vs. 46%; p = .005) had a smoking history. Logistic regression analysis revealed that the young age group (18–30) was less likely ( p = .002), whereas the middle age group (31–50) was more likely ( p < .001) to have a smoking history than those older than 50 years. Rural residence was associated with a smoking history among women ( p < .001), but not among men ( p = .70) in this sample. Conclusions: Tobacco control efforts are needed to focus on middle-aged men in general and women with rural residence history. Implications: Nurse practitioners are uniquely positioned to directly contribute to future research with self-identified rural populations that could help inform future public health policy.
Clinical Pharmacists and Industry: Guidelines for Professional Interactions
Irwin, Adriane N. , Spinler, Sarah A. , Baye, Jordan , Byerley, Summer Danielle, Evans, Emily, Florczykowski, Brittany , Fritz, Megan Kunka , Kawaguchi‐Suzuki, Marina, Johnson, Steven T. , Raheem, Farah , Rhee, Diane, Yogaratnam, Dinesh, Baye, Jordan F , Bulloch, Marilyn N , Byerley, Summer D , Florczykowski, Brittany , Fritz, Megan K , Kawaguchi-Suzuki, Marina , Johnson, Steven T , Raheem, Farah , Saad, Maha , Yogaratnam, Dinesh , Saad, Maha

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | February 20, 2026 | Volume: 9 | Issue: 3 | Pages: No page available

10.1002/jac5.70190 | PMID 42009499 Get It

ABSTRACT Interactions between clinical pharmacists and industry partners continue to evolve as health care increases in complexity and technology assumes a more dominant role. To address the corresponding ethical challenges, the 2025 Industry Relations Committee of the American College of Clinical Pharmacy (ACCP) was charged with updating the 2008 ACCP position statement, Pharmacists and Industry: Guidelines for Ethical Interactions . This update expands its perspective, reflecting the broader and more influential roles pharmacists play across the health care ecosystem. All clinical pharmacist–industry interactions should be grounded in improving patient care. Through this lens, six recommendations are provided: (1) Pharmacists should not engage in industry partnerships or collaborations that might unduly influence objectivity, independence, or fairness in clinical and professional judgments; (2) Pharmacists should disclose and mitigate financial, consulting, or other relationships that constitute potential conflicts of interest and should not participate in activities where an existing conflict cannot be resolved; (3) Pharmacists who participate in industry‐sponsored research should follow accepted ethical, regulatory, and scientific standards; (4) Pharmacists providing continuing education programs or developing drug information materials should maintain control of content; ensure their content is fair, balanced, and free from bias; and disclose and mitigate any conflicts; (5) Formal instruction on ethical interactions with industry professionals should begin early and continue through all stages of pharmacist education, training, and professional development; (6) Pharmacists should maintain the confidentiality and privacy of patients and other health care professionals when working with industry partners. Questions to guide personal industry interactions are provided. This paper does not detail every emerging area (e.g., artificial intelligence, social media), but recommendations are applicable wherever clinical pharmacists leverage their professional expertise. By maintaining a critical, discerning, and ethical approach to industry collaborations, clinical pharmacists can uphold professional obligations while contributing to the advancement of evidence‐based practice, ultimately prioritizing patient welfare.
White matter predictors of cerebellar tDCS treatment effects in aphasia rehabilitation
Keser, Zafer, Lammers, Becky , Sydnor, Myra, Murter, Jamie L., Zhang, Yiyang, Desmond, John E. , Sebastian, Rajani , Keser, Zafer , Johnson, Micah Alan , Keser, Zafer , Sadil, Patrick S. , Hillis, Argye Elizabeth , Lindquist, Martin A.

Mayo Clinic

Frontiers in Neurology | February 20, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fneur.2026.1659337 | PMID 41798805 Get It

Introduction Cerebellar transcranial direct current stimulation (tDCS) combined with language therapy can aid in chronic aphasia recovery, but the neural mechanisms and biomarkers of treatment efficacy remain uncertain. Methods In this secondary analysis of data from a previously conducted clinical trial, we used a randomized, double-blind, sham-controlled, within-subject crossover design with a study sample of 19 participants with post-stroke aphasia. We assessed the degree to which baseline properties of cerebro-cerebellar white matter tracts can predict or moderate longitudinal treatment effects at three time points: post-treatment, 2 weeks post-treatment, and 2 months post-treatment. Tract properties were measured by fractional anisotropy (FA) and mean diffusivity (MD) from diffusion tensor imaging (DTI). We also tested whether there are differential effects between trained and untrained language tasks and between cerebellar tDCS polarity (anodal and cathodal). Results Baseline measures of tracts connecting the left lesioned cortex to the right posterolateral cerebellum (stimulation target) influenced treatment gains for untrained tasks, relative to sham control. In contrast, for the trained task, treatment gains were influenced by baseline measures of tracts connecting the non-stimulated left cerebellum with the contralateral right cerebral cortex. Although there were no consistent effects from cerebellar tDCS polarity, a highly consistent pattern emerged across all tasks and tracts. Specifically, language improvements were predicted by a baseline tract profile (i.e., higher FA and lower MD) typically associated with higher white matter integrity, especially within the context of stroke-induced white matter decline. Discussion These findings corroborate the potential for baseline tract properties as a biomarker of treatment efficacy and support the notion that adjuvant (cerebellar tDCS + language) therapy preferentially benefits individuals with relatively preserved structural connections within functionally relevant networks. Clinical trial registration ClinicalTrials.gov , identifier (NCT02901574).
Pathway to Adaptive Neuromodulation: Modeling Epileptogenic Brain States Using SEEG
Makhoul, Ghassan S. , Reda, Anas, Lerma, Bruno Hidalgo Monroy, Fan, Joline M. , Worrell, Gregory A., Englot, Dario J., Englot, Dario J. , Lerma, Bruno Hidalgo Monroy , Reda, Anas , Hidalgo Monroy Lerma, Bruno , Fan, Joline M , Englot, Dario J , Johnson, Graham W. , Worrell, Gregory A.

Mayo Clinic

Epilepsy Currents | February 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15357597261422447 | PMID 41726571 Get It

Neuromodulation is becoming a common treatment strategy for patients with drug-resistant epilepsy who are not candidates for resective surgery. Responsive neurostimulation can effectively reduce seizure burden, however it remains unclear which neural signals are most important for triggered stimulation. Furthermore, the high-dimensional parameter space remains systematically underexamined. As more patients become candidates for neurostimulation, clinical teams will need to decide on the optimal site and stimulation program for therapeutic neuromodulation. In this review, we highlight how recent insight into the biological rhythms of epilepsy may pair with personalization protocols in the emerging field of neuropsychiatric neuromodulation. Finally, we discuss future directions for epilepsy neuromodulation, specifically how machine learning can offer clinical teams actionable feedback on neuromodulation efficacy.
Treatment for Brain Metastases With Stereotactic Radiation vs Hippocampal-Avoidance Whole Brain Radiation
Aizer, Ayal A., Shin, Kee-Young, Catalano, Paul J. , Ricca, Ivy, Johnson, Marciana, Benham, Grant, Röper, Kristin, Spicer, Beverly, Mann, Eileen, Nosker, Jennifer , Parsons, Michael W., Mendu, Mallika L. , Hepel, Jaroslaw T., Chipidza, Fallon , Krishnan, Monica, Shi, Diana, Lamba, Nayan, Pashtan, Itai , Peng, Luke, Alexander, Brian, Brown, Paul D., Wen, Patrick Y , Haas-Kogan, Daphne A., Rahman, Rifaquat M., Tanguturi, Shyam , Parsons, Michael , Parsons, Michael W , Tanguturi, Shyam K , Ricca, Ivy , Aizer, Ayal A. , Mann, Eileen, Shi, Diana D. , Lamba, Nayan , Haas-Kogan, Daphne , Rahman, Rifaquat

Mayo Clinic

JAMA | February 19, 2026 | Volume: 335 | Issue: 13 | Pages: 1127

10.1001/jama.2026.0076 | PMID 41712219 Get It

Importance Brain metastases are common in patients with cancer, and radiation is often used for management. Among patients with more than 4 brain metastases, the effects of stereotactic radiation targeting only individual tumors, compared with whole brain radiation with hippocampal avoidance, which radiates both tumors and normal brain, remain unknown. Objective To determine whether stereotactic radiation improves symptom severity and interference with daily functioning, compared with whole brain radiation with hippocampal avoidance. Design, Setting, and Participants Phase 3, open-label, randomized clinical trial conducted at 4 United States–based centers. Eligible patients had 5 to 20 brain metastases and no prior brain-directed radiation. Enrollment occurred between April 11, 2017, and May 17, 2024 (final follow-up, March 18, 2025). Intervention Stereotactic radiation, compared with whole brain radiation with hippocampal avoidance. Main Outcomes and Measures Mean weighted patient-reported symptom severity and interference score change over 6 months postbaseline relative to baseline using the MD Anderson Symptom Inventory–Brain Tumor instrument (scale, 0-10; score change range, −10 to 10; −10 = best). A clinically meaningful Δ was defined as 0.98. Results Of 196 randomized patients (mean age, 61 years; 129 [66%] female; 176 [90%] White; median number of brain metastases, 14 [IQR, 11-18]; 49 [25%] with prior neurosurgical resection), 83 (42%) completed the 6-month assessment. For the primary outcome, between baseline and postbaseline assessments through the 6-month follow-up, stereotactic radiation changed the weighted composite MD Anderson Symptom Inventory–Brain Tumor score from 2.69 to 2.37 (mean change, −0.32) and hippocampal-avoidance whole brain radiation changed the score from 2.29 to 3.03 (mean change, 0.74) (mean difference, −1.06 [95% CI, −1.54 to −0.58]; P &amp;lt; .001). Related grade 3-5 adverse events occurred in 12 patients (12%) in the stereotactic radiation group and 13 patients (13%) in the hippocampal-avoidance whole brain radiation group; grade 1-3 fatigue was most frequent (27 [28%] vs 43 [44%], respectively). Conclusions and Relevance In patients with 5 to 20 brain metastases, these findings support stereotactic radiation over hippocampal-avoidance whole brain radiation to improve symptoms and interference with daily functioning, key components of quality of life. Trial Registration ClinicalTrials.gov Identifier: NCT03075072